Aug 2 (Reuters) - Transcept Pharmaceuticals Inc:
* Purdue pharmaceutical products l.p. and Transcept Pharmaceuticals Inc sign
exclusive agreement to commercialize Intermezzo(R) in the United States
* Says FDA has established October 30 as prescription drug user fee act action
date for the intermezzo new drug application
* Purdue will pay Transcept cash payment of $25 million and additionally up to
$30 million based on timing of FDA approval of intermezzo
* Could receive up to $90 million upon reaching future milestones related to
achievement of intellectual property and u.s. net sales targets
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Transcept Pharmaceuticals Inc click here:) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Purdue pharmaceutical products l.p. and Transcept Pharmaceuticals Inc sign
exclusive agreement to commercialize Intermezzo(R) in the United States
* Says FDA has established October 30 as prescription drug user fee act action
date for the intermezzo new drug application
* Purdue will pay Transcept cash payment of $25 million and additionally up to
$30 million based on timing of FDA approval of intermezzo
* Could receive up to $90 million upon reaching future milestones related to
achievement of intellectual property and u.s. net sales targets
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Transcept Pharmaceuticals Inc click here:) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.